Disposable adjustable-dose platform

75U Peptide Injection Pen Platform

A 3 mL disposable source configuration documented to a 0.75 mL maximum.

Documented configuration

Primary container: Standard 3 mL cartridge
Dose increment: 0.01 mL
Dose units: 75
Dose / delivery range: 0–0.75 mL

Drug names describe source-listed or potential evaluation scenarios. Final compatibility, intended use and authorization require program-specific evidence.

Product overview

A 3 mL disposable source configuration documented to a 0.75 mL maximum. This platform is presented for technical screening; final suitability depends on the selected device configuration, formulation, primary container, use conditions and project-specific verification.

Source and evidence boundary

Published values are configuration-specific and remain subject to controlled internal evidence review. Supplier identities and source records are not public product claims.

Key product features

Standard 3 mL cartridge
0.01 mL documented increment
0–0.75 mL documented range

Technical specifications

The selected variant controls every value in this table. Values from other configurations are not merged.

Drug or application assessment

A 3 mL disposable source configuration documented to a 0.75 mL maximum. Listed applications are screening contexts only. Compatibility and regulatory conclusions require project-specific evidence.

Tirzepatide scenarioRetatrutide scenarioPeptide programs

Cartridge & needle compatibility

Standard 3 mL cartridge is the documented primary-container format. Final dimensions, stopper system, needle interface and component compatibility must be confirmed for the selected configuration.

OEM / ODM configuration

Dose systemVariant-specific range and increment

AppearanceColor, logo and dose-scale artwork

Primary packCartridge or PFS assessment

Secondary packLabeling and packaging pathway

Validation & documentation

Project scope may include configuration drawings, risk inputs, dose-delivery verification, container and needle assessment, transport or aging considerations, and human-factors planning. Availability depends on the selected platform and agreed program.

Questions for platform selection

What is the formulation?Viscosity, concentration and stability affect delivery-system assessment.

What is the primary container?Cartridge or PFS geometry, stopper and closure details must be confirmed.

What is the target dose?Minimum, maximum, increment and dosing sequence belong to one verified variant.

Who will use it?User population, training, dexterity and feedback needs shape human-factors work.

Which market?Documentation and regulatory pathways vary by intended region.

What is customized?Functional, labeling and appearance changes have different validation impacts.

Why evaluate this platform with Penacta

Penacta separates platform screening from final compatibility claims. Device architecture, formulation, primary container, dose profile, user needs and market pathway are reviewed as one combination-product problem.